Lantern Pharma Inc. Common Stock
LTRNLantern Pharma Inc. (LTRN) is a biotechnology company focused on developing personalized cancer treatments through the use of artificial intelligence and advanced data analytics. The company leverages its proprietary platform to identify targeted therapies and optimize clinical trial processes, aiming to improve outcomes for cancer patients.
Company News
Lantern Pharma, an AI-driven biotech company, is using machine learning and computational biology to accelerate cancer drug discovery, with three ongoing clinical trials targeting challenging and rare cancers.
Lantern Pharma, an AI-driven oncology biotech, reported improved Q2 2025 financial results with narrowed GAAP losses and promising clinical trial progress across multiple drug candidates, particularly in cancer treatments.
Lantern, a specialty care platform, announced a new partnership with the 32BJ Health Fund to provide access to high-quality surgeons and specialists at little to no cost for the union's members. This partnership aims to ensure affordable and accessible healthcare for the essential workforce represented by SEIU 32BJ.
Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, and enable the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billi...
